白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌的临床分析  

Albumin type combined with paclitaxel plus beacizumab bead sheet resistance for the treatment of recurrent ovarian cancer

作　　者：陈杰[1] 陈春婷[1] 关慧[1] 董丽娜[1] 刘睿敏 

机构地区：[1]哈尔滨医科大学附属第三医院妇科三病区,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2016年第7期1117-1119,共3页Journal of Modern Oncology

基　　金：黑龙江省教育厅科学技术研究项目(编号:12531386)

摘　　要：目的:探讨白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌疗效、不良反应和生存情况。方法:选取经病理学诊断为卵巢上皮癌患者78例,既往使用过紫杉类、吉西他滨等药物治疗后进展,接受白蛋白结合型紫杉醇联合贝伐珠单抗方案治疗。具体方案:第1天接受白蛋白结合型紫杉醇260mg/m2、第2天接受贝伐珠单抗15mg/m2,21d为1个周期,每个周期评价不良反应,2个周期评价疗效。结果:78例患者均可进行疗效评价,无完全缓解病例,部分缓解9例,稳定42例,进展27例,有效率为11.5%(9/78),临床获益率为65.4%(51/78)。主要不良反应为骨髓抑制、消化道反应、乏力、脱发、外周神经毒性、皮疹、高血压、肌肉酸痛,不良反应多为I级和II级毒性,患者对毒副作用均可耐受,未发生治疗相关性死亡。结论:白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌可获得较好的疗效,不良反应可以耐受。Objective： To study the curative effect of type albumin in combination with paclitaxel plus beacizumab bead sheet resistance in the treatment of recurrent ovarian cancer adverse reaction and survival conditions. Methods：We used type albumin in combination with paclitaxel plus beacizumab bead sheet resistance to treatment of 78 cases of recurrent ovarian cancer. 1st day type albumin in combination with paclitaxel 260 mg / m2,beacizumab bead sheet resistance to 15 mg / m2,21 d for a cycle. Results： All 78 patients can be evaluated curative effect,no complete remission cases,partial in 9 cases,stable in 42 cases,27 cases,effective rate was 11. 5%（ 9 /78）,the clinical benefit rate was65. 4%（ 51 /78）. The main adverse reactions were bone marrow suppression,gastrointestinal tract reaction,fatigue,hair loss,peripheral nerve toxicity,skin rashes,high blood pressure,muscle aches. More adverse reactions were level I and level II,the side effects can be tolerated,no treatment- related death. Conclusion： The combination of albumin type paclitaxel plus beacizumab bead sheet resistance in the treatment of recurrent ovarian cancer can obtain better curative effect,adverse reactions can be tolerated,but still needs further research.

关 键 词：复发性卵巢癌 白蛋白结合型紫杉醇 贝伐珠单抗 

分 类 号：R737.31[医药卫生—肿瘤]